Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.-Reference-Cited by-同舟云学术

Induction chemotherapy backbone in frail patients with advanced NSCLC treated with chemotherapy plus pembrolizumab: a single institution retrospective audit of dose intensities from modified regimens.

Published:2024-08-06 Issue: Volume: Page:1-9
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Cortellini Alessio¹²³,Citarella Fabrizio²⁴^ORCID,Vendittelli Alessia¹²,Fiorenti Matteo¹²,Mingo Emanuele Claudio¹²,Cascetta Priscilla⁵,La Cava Giulia¹²,Santo Valentina¹²,Brunetti Leonardo¹²,Di Fazio Giuseppina Rita¹²,Fioroni Iacopo¹,Pantano Francesco¹²,Vincenzi Bruno¹²,Russano Marco¹,Minotti Giorgio²⁶,Tonini Giuseppe¹²

Affiliation:

1. Operative Research Unit of Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy

2. Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy

3. Department of Surgery and Cancer, Hammersmith Hospital Campus, Imperial College London, London, United Kingdom

4. Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), Meldola, Italy

5. Department of Cancer Medicine, Gustave Roussy Cancer Campus, Villejuif, France

6. Operative Research Unit of Clinical Pharmacology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2024.2388474

Reference23 articles.

1. Management of patients with non-small cell lung cancer and poor performance status

2. Lung Cancer in Elderly Patients: An Analysis of the Surveillance, Epidemiology, and End Results Database

3. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update

5. Immunotherapy for nonsmall cell lung cancer: a new therapeutic algorithm